Daniela R. Hernandez
Internal Medicine
205 E Toronto Ave
Mcallen, TX 78503
Mcallen, TX 78503
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Natural history of 15 patients with autosomal dominant WFS1 pathogenic variants associated with sensorineural hearing loss and optic atrophy.
Journal: Orphanet journal of rare diseases
Published: November 04, 2025
Natural history of patients with autosomal dominant WFS1 pathogenic variants associated with sensorineural hearing loss and optic atrophy.
Journal: medRxiv : the preprint server for health sciences
Published: March 10, 2025
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Journal: Haematologica
Published: April 27, 2022
Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia.
Journal: Bone marrow transplantation
Published: April 14, 2020
A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia.
Journal: Haematologica
Published: January 16, 2020
Overcoming microenvironment-mediated protection from ATRA using CYP26-resistant retinoids.
Journal: Leukemia
Published: November 14, 2019
Regulation of drug metabolizing enzymes in the leukaemic bone marrow microenvironment.
Journal: Journal of cellular and molecular medicine
Published: February 03, 2019
Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.
Journal: Cancer
Published: July 21, 2017
Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
Journal: Blood
Published: December 03, 2016
Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance.
Journal: The Journal of clinical investigation
Published: April 19, 2016
Showing 1-12 of 12
Last Updated: 09/26/2026